Startups
2020
PULMOBIOTICS SLTechnology to discover and develop novel treatments and vaccines for respiratory diseases
A novel live biotherapeutic platform for treating human lung diseases.
A novel live biotherapeutic platform for treating human lung diseases.
Finance Data
CERCA ownership
Barcelona, Spain
2000
Centre de Regulació Genòmica (CRG)
Other Catalan Public owners
Logo
Status & Deeptech areas
Company Status & Company Deeptech AreasCurrent company status
DeepTech Area
Spinoff information
Company Description
A spin off company from the Centre for Genomic Regulation (Barcelona - Spain) founded by experienced entrepreneurs and funded by invivo Ventures.
Using a proprietary microbial engineering and synthetic biology toolbox our founders have created a platform based on attenuated lung bacteria that is able to expose antigens or deliver therapeutic agents in the lung in a controlled, local and continuous manner.
Pulmobiotics SL will use this technology to discover and develop novel treatments and vaccines for respiratory diseases, which are among the most common causes of severe illness and death worldwide.
Using a proprietary microbial engineering and synthetic biology toolbox our founders have created a platform based on attenuated lung bacteria that is able to expose antigens or deliver therapeutic agents in the lung in a controlled, local and continuous manner.
Pulmobiotics SL will use this technology to discover and develop novel treatments and vaccines for respiratory diseases, which are among the most common causes of severe illness and death worldwide.
Product description
Our platform is based on attenuated lung bacteria able to expose antigens or deliver therapeutic agents in the lung in a controlled, local and continuous manner. It allows engineering of multiple genetic circuits to specifically target and deliver payloads.
Our VAP product uses attenuated lung bacteria to deliver therapeutic agents with antibacterial activity in the lung in a controlled, local and continuous manner.
This product has already demonstrated activity in vitro and in animal models.
Our VAP product uses attenuated lung bacteria to deliver therapeutic agents with antibacterial activity in the lung in a controlled, local and continuous manner.
This product has already demonstrated activity in vitro and in animal models.